答：根据近期市场行情，VC 产品价格整体保持稳定。产品价格 受原材料成本、市场供需关系、行业库存等多重因素综合影响，具 有不确定性。从目前来看，下游需求端保持增长。公司对二季度的 市场展望持谨慎乐观态度，并将继续通过精益管理控制成本，提升 产品竞争力。具体的价格走势受宏观环境影响较大，敬请投资者注 意投资风险。 4. 主营业务原料药及中间体、微生物蛋白今年的经营目标？ 江西富祥药业股份有限公司 投资者关系活动记录表 | 证券代码：300497 | 编号：20260302 | 证券简称：富祥药业 | | --- | --- | --- | | | □ 特定对象调研 □ 分析师会议 | | | 投资者关系活动 | 媒体采访 业绩说明会 □ □ | | | 类别 | 新闻发布会 路演活动 □ √ | | | | 现场参观 其他 □ □ | | | 参与单位名称及 | 国金证券、中金基金、博时基金、摩根基金、中航基金、东方基金、 | | | 人员姓名 | 华福资管、中哲物产、中加基金、紫金信托、湖南长心私募、德邦 | | | | 基金、交银理财、玄元投资、盘京投资、海富通基金、光大永明资 | | | | 产、上海信托 ...

Group 1: Company Overview - In 2024, the pharmaceutical industry faced intensified competition, leading to a 10.75% decline in product prices [2] - The company achieved a net profit attributable to shareholders of -3.30 billion yuan, a year-on-year increase of 21.38% [2] - In Q1 2025, the company reported revenue of 4.86 billion yuan and a net profit of 651.46 million yuan after excluding non-recurring gains [2] Group 2: Product and Market Strategy - The company is focusing on strengthening its core product base while increasing R&D for new products [2] - The company has diversified its raw material drug pipeline into multiple therapeutic areas, including anti-infectives and dermatology [3] - The company is expanding its CMO/CDMO projects, with several potential collaborations in the pipeline [3] Group 3: Dye Business Insights - The dye segment includes high-performance eco-friendly dyes, with the main product KN-R recognized as a "Manufacturing Industry Single Champion Product" [4] - The company is adopting an integrated business model from basic chemical raw materials to dye intermediates and dyes, enhancing resource allocation and production efficiency [4] - Due to market changes and rising raw material costs, the company has adjusted prices for some dye products [4]